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Pharmaco-genomic investigations of organo-iridium
anticancer complexes reveal novel mechanism of
action†
Jessica M. Hearn,‡ab George M. Hughes, ‡ac Isolda Romero-Canelo´n, ad
Alison F. Munro,e Bele´n Rubio-Ruiz, e Zhe Liu, af Neil O. Carragher *e and
Peter J. Sadler *a
Resistance to platinum drugs (used in 450% of cancer chemotherapies) is a clinical problem. Other
precious metal complexes with distinct mechanisms of action might overcome this. Half-sandwich
organometallic complexes containing arene or cyclopentadienyl (Cp) ligands show promise. We screened
two iridium(III) complexes [Ir(CpXbiph)(ppy)Cl] (ZL49, 1, ppy = phenylpyridine) and [Ir(CpXph)(azpyNMe2)Cl]PF6
(ZL109, 2, azpyNMe2 = N,N-dimethylphenylazopyridine) in 916 cancer cell lines from 28 tissue types. On
average, complex 2 was 78 more potent than 1, 36 more active than cisplatin (CDDP), and strongly
active (nanomolar) in patient-derived ovarian cancer cell lines. RNA sequencing of A2780 ovarian cells
revealed upregulation of antioxidant responses (NRF2, AP-1) consistent with observed induction of reactive
oxygen species (ROS). Protein microarrays, high content imaging and cell cycle analysis showed S/G2
arrest, and late-stage DNA damage response without p53 requirement. The triple-negative breast cancer
cell line OCUB-M was highly sensitive to 2 as were cell lines with KIT mutations. Complex 2 exhibits a
markedly diﬀerent pattern of antiproliferative activity compared to the 253 drugs in the Sanger Cancer
Genome database, but is most similar to osmium(II) arene complexes which share the same azopyridine
ligand. Redox modulation and DNA damage can provide a multi-targeting strategy, allowing compounds
such as 2 to overcome cellular resistance to platinum anticancer drugs.
Significance to metallomics
Half-sandwich organoiridium complexes show promising activity, with novel mechanisms of action that may combat platinum resistance and side eﬀects seen
commonly in current anticancer chemotherapy regimes. The field of systems pharmacology provides methods to elucidate the often multitargeted mechanisms
of metallodrugs. Here, we explore the link between transcriptomic and phenotypic data in ovarian cancer cells, using state-of-the-art high-throughput methods,
together with data collected from Sanger’s Genomics of Drug Sensitivity in Cancer screen and primary tumour cell lines. Our studies ultimately reveal not only
the subtle eﬀects of ligands on complex activity, but unique mechanisms shared only with osmium arene complexes.
Introduction
The square-planar platinum drugs cisplatin (CDDP), carboplatin
and oxaliplatin are now used in over 50% of cancer chemo-
therapies, but intrinsic and acquired resistance represent
major clinical problems across cancer indications. CDDP has
a primary mechanism of action (MoA) which involves DNA
targeting, induction of DNA bending, and apoptosis.1 Other
precious metal complexes might be able to overcome resistance
if they have diﬀerent MoAs. This appears to be the case for
platinum drug oxaliplatin and candidate drug phenanthriplatin,
which are not cross-resistant with CDDP. Although oxaliplatin is
classified as a DNA alkylating agent like CDDP, recent evidence
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now points primarily to ribosome biogenesis stress, rather than
DNA damage.2
Pseudo-octahedral ‘half-sandwich’ organometallic arene
and cyclopentadienyl complexes also show promise for over-
coming platinum resistance. Osmium(II) arene complexes
and iridium(III) cyclopentadienyl (CpX) complexes [M(arene/
CpX)(N,N)(X)]n+ can target DNA when N,N is a chelated diamine
ligand.3,4 In contrast, when N,N is an azopyridine ligand, the
complexes can cause redox stress in cancer cells and target
mitochondrial metabolism.5–8 Azopyridine ligands are strong
p-acceptors and withdraw electron density from the metal
making the M–C bond to the monodentate ligand X (e.g. Cl
or I) much less reactive.
We have discovered potent antiproliferative activity for organo-
Os(II) and organo-Ir(III) complexes by phenotypic screening and
have shown that screening in the National Cancer Institute
(NCI-60) and Sanger 800+ panel of cancer cell lines when com-
bined with transcriptomics, reactive oxygen species (ROS), protein
micro-arrays, high content imaging and other assays can provide
valuable insight into their MoAs.9,10
Here we report the results of phenotypic screening and
in-depth MoA profiling of two organo-iridium(III) complexes
(Fig. 1) [Ir(Z5-CpXbiph)(ppy)Cl] (ZL49, 1, ppy = phenylpyridine)
and [Ir(Z5-CpXph)(azpyNMe2)Cl]PF6 (ZL109, 2, azpyNMe2 =
N,N-dimethylphenylazopyridine) in the Sanger Cancer Genome
project panel of 916 cancer cell lines with known gene sequences
from 28 tissue types. Time-dependent up- and down-regulation of
genes has been studied by RNA sequencing, together with the
detection of selected proteins and quantitative analysis of cell
cycle, and apoptosis phenotypes.
These studies point to a unique MoA for organo-iridium
complexes with little in common with previously-screened agents,
except organo-osmium complexes.
Results
Antiproliferative activity
Initially, we screened organo-iridium complexes 1 ([Ir(Z5-CpXbiph)-
(ppy)Cl]) and 2 ([Ir(Z5-CpXph)(azpy-NMe2)Cl])PF6 in the NCI-60
screen.8,11 Complex 2 was more active than 1, however both were
potent with mean IC50 values of o1 mM, more potent than the
clinical drug CDDP. Both compounds were particularly active in
colorectal cell line COLO205 and breast cell line MDA-MB-468,
with renal cell lines showing resistance (much lower sensitivity)
to both.
The higher activity of complexes 1 and 2 towards COLO205
and MDA-MB-468 can be attributed to redox deficiencies in
these cell lines. COLO205 colorectal cells have reduced levels of
glutathione-S-transferase P1 (GSTP1), an enzyme which detoxifies
drugs by conjugating them to glutathione (GSH) often limiting
the eﬃcacy of anticancer agents.12 Without this enzyme, there
may be less conjugation and inactivation by GSH, which could
increase the sensitivity of cells towards anticancer compounds.
The breast cell line, MDA-MB-468 showed a consistently
high sensitivity in the NCI-60 screen (IC50 values 17 nM to
1.8 mM). This cell line has a glucose 6-phosphate dehydrogenase
(G6PD) A phenotype, meaning it lacks the proper functioning of
this enzyme in the pentose phosphate pathway.13 G6PD is the
rate-limiting enzyme in this pathway; its deficiency blocks the
conversion of glucose-6-phosphate to 6-phosphoglucono-D-lactone
and in the process prevents the conversion of NADPH to
NADP+, a required step in GSH synthesis.14 This suggests that
a GSH deficiency may play an important role in potentiating
the activity, something previously demonstrated when A2780
cells were co-incubated with low levels of the GSH inhibitor,
L-buthionine sulfoximine. Multiple studies have shown that
this deficiency prevents the cells from mediating oxidative
stress, and often results in apoptosis and necrosis of cells in
patients.15
Comparison of the patterns of selectivity for both complexes
with those of 440 000 synthetic compounds and natural pro-
ducts in the NCI database and drugs that showed a Pearson’s
correlation coeﬃcient (r) 4 0.5, revealed only 3 drugs with
similar patterns of selectivity to that of 1 and 2, highlighting
their novelty.
Now we have screened complexes 1 and 2 in 916 cell lines
from 28 tissue types in the Sanger Cancer Genome project
panel and compared the patterns of antiproliferative activity
with the 256 compounds in the ‘Genomics of Drug Sensitivity in
Cancer’ database.16
In Fig. 2, the IC50 values for 1 and 2 and CDDP are compared
for 809 cell lines in the screen using box and whisker plots. On
average across all cell lines, complex 2 is 78more potent than
complex 1 and 36 more potent than CDDP.
Complex 2 exhibits its highest mean activity in cancers of
testicular, urogenital, cervical and uterine tissues, although the
number of cell lines derived from these tissues is considerably
lower than for many of the other tissue types. Complex 1 shows
its highest activity in the SU-DHL-5 lymphoma cell line; however,
this potency is lower than that of 2 and CDDP.
Fig. 1 Organo-Ir(III) complexes 1 and 2 and organo-Os(II) complexes 3
and 4 referenced in this work.
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Complex 2 displays its highest activity in the OCUB-M breast
cancer cell line, and notably is ca. 5 orders of magnitude more
active than CDDP. OCUB-M is a triple negative breast cancer cell
line with high expression of E-cadherin and laminin receptors.17
There are 10 genetic mutations in this cell line, one of which is a
missense mutation in p53. As mentioned above, in previous
work it was also shown that MDA-MB-468, another triple nega-
tive cell line, had significant susceptibility to 2.8 Triple-negative
breast cancer is particularly diﬃcult to treat; therefore further
studies of 2 in this area would seem warranted.
Complex 2 and the organo-osmium complex FY12 (complex 4
in Fig. 1), which notably contains the same chelated azopyridine
ligand, are amongst the 15 most potent drugs screened against
OCUB-M in the Sanger panel. Five others are microtubule-
targeting drugs, constituting all the drugs in this category in the
screen. The successful treatment of OCUB-M with microtubule
inhibitors may be linked to the over-expression of TUBG1 (tubulin
SF) and MAP7 (microtubule-associated protein) and the down-
regulation of MAP1LC3B (microtubule associated protein 1 light
chain 3 beta), MICAL-1 (microtubule associated monooxygenase,
calponin and LIM domain containing 1) and TTBK2 (Tau tubulin
kinase). The over-expressed genes mediate microtubule formation
and stabilisation. The down-regulated genes can cause destabili-
sation and depolymerisation of tubulin and actin, respectively.
Although sensitive to complex 2, OCUB-M is highly insensitive
to CDDP. This might be linked to mutations in its p53 protein,
Fig. 2 Box and whisker plots for log IC50 (mM) values, complex 1 (blue), 2 (green) and CDDP (red) in the Sanger screen, separated by tissue type.
N denotes the number of cell lines of each tissue type in the screen. The red circle denotes the IC50 value for the breast cancer line OCUB-M that exhibits
extreme sensitivity to 2 and, in contrast, low sensitivity to both 1 and CDDP. Total number of cell lines included = 809 (to match the cell lines screened
against CDDP). IC50 values which fall outside the experimental screening concentrations were calculated using a curve-fitting algorithm, and as such
have a large confidence interval.16
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which has been repeatedly correlated with CDDP resistance.18
Fig. S1 (ESI†) shows the distribution of IC50 values for 1, 2 and
CDDP, where boxes show the median, upper and lower quartiles.
The red lines mark the threshold for lower sensitivity compared
to complex 2. Complex 2 shows considerably higher activity
than complex 1 (by 78) and CDDP (by 36), as well as being
significantly more potent when compared to the mean activity
over all ca. 200 drugs included in the screen (Table S4, ESI†).
The IC50 values for 46 of the 916 cell lines lie above the upper
whisker threshold for 2. This population of less sensitive cell
lines falls within the activity ranges of 1 and CDDP. The
occurrence of so many cell lines far outside the interquartile
range for 2 might be due to a common resistance feature,
although may also reflect the tighter spread amongst values for
the more sensitive cell lines.
Table 1 lists the 10 cell lines exhibiting the lowest sensitivity
to complex 2. The tissue types displaying the highest percentages
are lymphoma, myeloma and leukemia, each with 410% of
their population less sensitive to 2 (Fig. S2, ESI†). These parti-
cular tissues make up the blood-derived cancers. Although some
factor specific to tissues derived from the embryonic mesoderm
may contribute to the low sensitivity, other mesodermally-
derived tissues, such as bone, urogenital and kidney tissue do
not exhibit a large proportion of resistant cells, making it more
likely that some other feature of blood-derived cancers confers
resistance. Cancers of ectodermally-derived tissues such as the
skin and nervous system show little or no cell lines in the
resistant population.
It is apparent that resistance to piperlongumine treatment
is common for these cell lines: 19 out of 46 cell lines least
sensitive to complex 2 can also be classified as resistant to
piperlongumine, an organic natural product isolated from the
fruit of the pepper plant Piper longum. Piperlongumine has
been evaluated as a novel senolytic agent, selectively inducing
death of senescent cells,19 killing cancer cells by targeting the
stress response to ROS.20
The level of similarity between 1 and 2 and other drugs in the
screen was evaluated from diﬀerences in their IC50 values. To
account for the fact that large positive and large negative diﬀer-
ences could cancel each other out, the standard deviations of these
diﬀerences were also calculated. A drug was considered similar to
the index drug if the total mean diﬀerence in IC50 was close to zero
and the SD was low (denoted by the red circle in Fig. 3).
Intriguingly, the data for iridium complex 2 matched most
closely those of FY12 ([Os(Z6-bip)(azpy-NMe2)I]
+) and FY26
([Os(Z6-p-cym)(azpy-NMe2)I]
+), (complexes 4 and 3 respectively,
in Fig. 1) two organo-osmium compounds studied previously in
our laboratory.21 FY12/FY26 and 2 share the same bidentate
azopyridine ligand, but have diﬀerent C-bound p-donor ligands
(neutral arene versus negatively-charged cyclopentadienyl),
diﬀerent monodentate halido ligands (chloride versus iodide)
as well as metal centres (Os(II) versus Ir(III)). The much higher
similarity of these two matches to complex 2 compared to other
drugs tested in the screen is evident, demonstrating novelty in
the MoA of complex 2 (Fig. 3).
To extract significant correlations between activity and
oncogenic behaviour of compounds from the Sanger screen,
an analysis of variance (ANOVA) test can be used. The dependent
variable is presented as an n  2 matrix for each compound,
containing IC50 and b (slope) values, and therefore, a multi-
variate ANOVA (MANOVA) is used for the analysis. For each gene,
a linear model explains these activity observables with ‘mutation
status’ as the predictive variable. Only genes mutated in42 cell
lines were included in the analysis, and a Benjamin–Hochberg
multiple testing correction was used to identify significant
results (FDR o 0.20). This quantitative assessment of pharma-
cogenomics uses an effect size parameter, calculated between
wild type and mutant populations. If the effect size is 41, the
difference in mean value between the mutated and wild-type
populations is greater than the variance in at least one popula-
tion, and the effect is therefore large.
It is evident that when the CASP8 gene is mutated, cells
become sensitized to 1 (Table 2). This gene encodes caspase-8,
which is involved in apoptosis and signalling cascades through
TNF and NFkB. The only other drug in the screen for which CASP8
coding mutation confers sensitivity is ABT-888 (veliparib), a PARP
inhibitor. The PARP family of proteins are involved primarily in
DNA repair and induction of programmed cell death. Where the
DNA damage is beyond repair, PARP is inhibited so as to preserve
cell ATP. The cell then undergoes programmed cell death.
The KIT gene coding mutation is associated with the sensi-
tivity of four NSCLC cell lines to complex 2, and encodes the
human homolog of the proto-oncogene C-KIT, a type-III trans-
membrane receptor for the stem cell growth factor. Once bound
to growth factor, this protein activates signal transduction
through the cell, aﬀecting cell survival and diﬀerentiation.
Table 1 The 10 cell lines least sensitive to complex 2 (IC504 150 mM). The drug in the database associated with the lowest sensitivity for each cell line is
also shown, together with the target of that drug
Subtype Cell line Resistance drug Drug target
Lung LU-65 Vorinostat and piperlongumine HDAC
NCI-H2081 Piperlongumine Increases ROS levels
NCI-H2135 Piperlongumine Increases ROS levels
Lymphoma WSU-DLCL2 LAQ824 HDAC
A4-Fuk N/A N/A
Aerodigestive ESO51 Piperlongumine Increases ROS levels
OACM5-1 TW 37 BCL-2, BCL-XL
Leukemia PF-382 Piperlongumine Increases ROS levels
Myeloma U-266 NU-7441 DNAPK
Stomach NCI-SNU-1 BEZ235 PI3K, mTORC1/2
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Matched pairs of patient-derived platinum sensitive and
resistant ovarian cancer cell models
Matched pairs of ovarian cancer cells directly isolated from
patients before and after relapse to platinum therapy are likely
to better represent clinical drug resistance and relapse mecha-
nisms relative to drug resistant cell clones generated following
in vitro drug exposure. Complexes 1 and 2 were tested in the
matched patient-derived ovarian cancer cell lines PE01 (patient
prior to treatment), PE04 (patient after taxane/platinum treatment)22
and also PE01-CDDP (PE01 cells exposed to low levels of CDDP
in vitro to create Pt resistance), Table 3.
It can be seen from Table 3 that complex 2 maintains high
activity in all 3 patient-derived cell lines. Conversely, 1 has poor
activity in PE01 and loses activity in cells from patients treated
with taxane/CDDP and even more so in CDDP-resistant cells.
This shows that the activity of 2 is unaﬀected by CDDP and/or
taxane resistance in these ovarian cell lines, unlike 1, suggesting
a lack of cross resistance due to its diﬀerent MoA. Given the rise
in occurrence of clinical platinum resistance, this is a promising
finding for complex 2.
Gene expression analysis
To investigate the MoA of the more active complex 2, A2780
ovarian cancer cells were exposed to the IC50 concentration
(0.40 mM) and the diﬀerential gene expression was explored using
RNA sequencing across a 48 h time series; measuring gene expres-
sion after 4, 12, 24 and 48 h exposure. Approximately 30 million
50 bp, paired-end reads were generated per sample, and sequence
reads were mapped to the hg19 (GRCh37) human genome (acces-
sion E-MTAB-5991). Table S1 (ESI†) gives the sequencing statistics
for the experiment.
Fig. S3 (ESI†) shows multidimensional scaling (MDS) plots for
complex 2- and control-exposed samples across the time series.
These plots are a means of visualising the level of similarity in
sample sets, by placing each of them in N-dimensional space,
where between – object distances are preserved.
The MDS plots show natural separation of the samples into
clusters, and good agreement between the triplicate measure-
ments. The biggest source of variation is by time point, followed
by exposure-status, i.e. whether they are exposed to a control or
to complex 2. Fig. S3B (ESI†) provides clear evidence that the
samples exposed for 48 h are significantly diﬀerent from those
exposed for shorter time periods, both in the control and in the
compound-exposed samples.
Fig. 3 Scatter plot of the mean diﬀerence in log IC50 values (mM) between all screened drugs and complex 2 (ZL109) vs. the SD of these diﬀerences. The
red circle of radius 0.7 standard deviations denotes a ‘region of significant similarity where the mean diﬀerence and standard deviation are low. The
similarity with two osmium arene complexes which share the same chelated azopyridine ligand (complexes 3 (FY26) and 4 (FY12), Fig. 1) is evident.
Table 2 Mutated genes most significantly correlated to the activity of
complexes 1 and 2. The eﬀect size measures the significance of this
correlation between genomic status and cell susceptibility, the higher
the eﬀect size, the higher the correlation
Complex Mutated gene No. cell lines Eﬀect size FDR
1 CASP8 17 0.57 0.18
2 KIT 4 0.83 0.08
Table 3 IC50 values for complexes 1 and 2 in patient-derived cancer cell
lines. PE01 patient prior to treatment, PE04 patient after taxane/platinum
treatment and PE01-CDDP cells from PE01 exposed to low levels of CDDP
in vitro to create Pt resistance
Complex Cell line IC50 (mM)
1 PE01 22.4
PE04 64.3
PE01-CDDP 110.3
2 PE01 1.21
PE04 1.65
PE01-CDDP 1.56
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Fig. S4A (ESI†) shows the number of diﬀerentially expressed
genes (DEGs) at 4, 24 and 48 h, and highlights where diﬀer-
ential expression overlapped. Fig. S4B (ESI†) shows the number
of those genes that were up- or down-regulated across the
series. The highest number of diﬀerentially expressed genes
was found after 12 h exposure (746) and 24 h (719), with
significant diﬀerential expression (DE) after just 4 h exposure
(349). Fig. S4B (ESI†) shows that at 12 h, there is significantly
more down-regulation than up-regulation, almost a 2 : 1 ratio,
compared to 24 h, where there is ca. 1 : 1 ratio of up- and down-
regulation.
We carried out pathway analysis with Ingenuity Pathway
Analysis software which uses an extensive literature database
(Ingenuity Knowledge Base) to integrate biological and chemical
pathway perturbation information.23 DEGs with 1.0 o LogFC 4
1.0 and FDRo 0.05 were assigned to biological pathways. Table S2
(ESI†) shows the top five upstream regulators of these pathways,
across the time series. The tables show the p value as calculated by
a hypergeometric test of over representation, and the z-score that
describes the extent of activation/inhibition of each pathway. One
of the hurdles with using high-content assays is that a drug’s
MoA can be swamped by larger cellular responses, like cell
survival/death and stress signalling which control often over-
lapping downstream processes. This makes it diﬃcult to pinpoint
the MoA, however, these results show that cells activate stress
response pathways even after short times of exposure to organo-
iridium complex 2.
Since previous studies on complex 2 suggested that oxidative
stress may be a part of its MoA, we examined the DE of oxidative
stress response markers (Fig. 4).8 The NRF2 transcription factor
(encoded by the NFE2L2 gene) is involved in an important anti-
oxidant response pathway, binding to the hARE (human anti-
oxidant response element) cis-element to transactivate detoxifying/
antioxidant genes. AP-1 complexes C-FOS/C-JUN and FRA-1/c-JUN,
encoded by FOS, FOSL1 and JUN genes, compete with NRF2 for
binding to hARE to active antioxidant genes. Two domains of
NRF2 cooperatively bind CBP, a CREB binding protein, and
synergistically activate transcription.24
Even though NFE2L2 is up-regulated throughout the time
series in response to 2, the MAF co-factor is significantly down-
regulated. Of the two AP-1 complexes, FRA-1 (FOSL1) is up-regulated
throughout the time series, showing significant DE after just
4 h and highest expression after 24 h. The second AP-1 complex,
with C-FOS (FOS) is also up-regulated for 2, with the biggest
response at 4 h, suggesting that the AP-1 complex may play a
role during early exposure, and the FRA-1 complex a role in later
exposure. Collectively this shows that all three transcription
factors for oxidative stress response, NRF2 and the two AP-1
complexes, play a role in the cellular response to 2.
Only a selection of antioxidant genes downstream of the
transcriptional activators are up-regulated, and those that are
up-regulated are not drastically so. Antioxidant genes CAT (cata-
lase) and EPHX (epoxide hydrolase), are both down-regulated. GSR
(glutathione reductase) and NQO (NADP(H) quinone oxido-
reductase) are both up-regulated. The low-level expression of
downstream eﬀectors may suggest that A2780 ovarian cancer
cells have a poor mechanism for responding to ROS.
Using flow cytometry, measurements were taken to assess
the capability of 2 to generate ROS and superoxide (SO) in
A2780 cells after 24 h exposure at IC50 concentration at 310 K
(Fig. S5, ESI†). Table S3 (ESI†) highlights the results and shows
a significant production of total ROS and SO in 84% of cells
exposed to complex 2, with the remaining 16% still showing
significant levels of total ROS alone.
Given the similarity of iridium cyclopentadienyl complex 2
and osmium arene complex 3 (FY26) in the Sanger screen, the
regulation of the ROS response pathway, as seen by RNA analysis,
was also compared. In previous work, the same cell lines were
exposed to FY26 at its IC50 concentration with the same protocol
used here; DEGs were analysed across a 48 h time series
(Fig. S6, ESI†).
Interestingly, although both compounds induce an oxidative
stress response, there are diﬀerences in the components of the
pathway that are up- and down-regulated. For example, FOS is
up-regulated in response to iridium complex 2, but down-
regulated in response to osmium FY26. This suggests that the
Fig. 4 Heat map of DEGs in the oxidative stress response pathway over the 48 h exposure of A2780 human ovarian cancer cells to complex 2. Only
DEGs with FDR o 0.10 are included.
Paper Metallomics
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
2/
12
/2
01
7 
14
:0
0:
32
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2017 Metallomics
oxidative stress response to complex 2 activates both AP-1
complexes, but activates only one in response to FY26.
Comparison of flow cytometry data for ROS measurements
also supports a diﬀerence in the ROS levels in cells responding to
2 compared to FY26.6 For example, when exposed to FY26, 95%
of cells showed high total ROS and high SO levels, compared to
the 84% in response to 2. Yet, the levels of total ROS alone were
drastically reduced in response to FY26, with only 2.5% of cells
in this state, compared to 16% in response to 2.
The apoptotic cell response in Fig. S7 (ESI†) shows signifi-
cant down-regulation of eﬀector caspases after 12 h (CASP-9, -6,
-2, -3 and -7). Genes for inhibitors of apoptosis proteins (IAP),
which inhibit the activation of caspase proteins, such as BIRC2
and more significantly BIRC3, are up-regulated after 4 h. BIRC5,
which codes for survivin, another IAP, was down-regulated
throughout the time series, suggesting specific modulation of
apoptotic signals through caspase inhibition.
Protein microarrays
Zeptosens reverse phase protein microarrays (RPPA) were used
to study the cellular levels of key proteins in 2-exposed cells
versus controls. RPPA measures the abundance of total protein
levels and phosphorylated proteins using epitope-specific anti-
bodies. The Relative Fluorescence Intensity (RFI) values obtained
for each protein, following secondary fluorescent antibody detec-
tion, were normalized to a house-keeping protein in each sample
(prohibitin) before the ratios of RFI between 2-exposed and
control samples were determined across the time-series (4, 24,
48 and 72 h), to quantify the abundance of total protein and
phospho-epitopes relative to vehicle (DMSO) controls. Given the
similarity in the Sanger screen between iridium complex 2 and
the osmium complex 3 (FY26), we compared our previously
published RPPA data to those of 2 to explore the DNA damage
response.
During cellular response to DNA damage, ATM, among other
proteins, is mobilised and auto-phosphorylated to ATM*, which
in turn phosphorylates CHK2 to CHK2*. At this point, the
response pathway branches into a rapid response via CDC25A,
and a delayed response via p53 and p21. Fig. 5 shows that the
protein response reaches a peak at 24 and 72 h exposure, for
both complex 2 and FY26.
CHK2*, CDC25A and p53* all show increased levels in
response to both compounds. However, only 2 appears to mobi-
lize a BRCA1 DNA damage response after 24 h, and primarily at a
low concentration.
Additionally, after exposure to 2, M-phase markers are
detected, something not seen for FY26. For example, there is
a high level of b-tubulin in response to 0.15 mM 2 at both 24 and
72 h, with an additional increase in the levels of CDK1. This
suggests that cells still have the proteins available to allow
progression from G2 to M phase of the cell cycle. At the higher
dose of 2, both tubulin and CDK1 levels do not change from the
control at 24 h. The higher levels of Rb* protein at 24 h suggest
that cells have passed, or are at least able to pass, the G1/S
transition point. This is not seen for FY26, for which levels of
these proteins are lower in compound-exposed cells. Therefore,
in response to 2, cells may be held in late S phase, or G2 phase
of the cell cycle, whereas in response to FY26 cells are more
likely held in G1 phase.25
Flow cytometry experiments were performed on A2780 cells
exposed to complex 2 and compared to those reported for FY26,
to detect the populations of cells in various stages of the cell
cycle (Fig. 6). The red fluorescence of propidium iodide (PI) dye,
which intercalates into DNA, correlates with the DNA content of
the cells, and is twice as high in G2/M as in G0/G1 cells.
After 24 h exposure to 2, the population of cells in the S
phase of the cell cycle had increased, with subsequent G1 and
G2/M populations decreasing. Conversely, exposure to 3 (FY26)
caused G1 arrest, with lower levels of cells populating the
S-phase. S-phase arrest is often associated with compounds that
cause DNA damage, suggesting this could be a more prominent
part of the MoA for complex 2.
RPPA was also used to study further the diﬀerential levels
of eighteen apoptotic proteins; five pro-survival proteins and
thirteen pro-apoptotic proteins, in cells responding to 2 across
Fig. 5 DDR/cell cycle investigations. Heat map showing the relative
fluorescence intensity (RFI) values for a selection of DNA damage response
(DDR) proteins in cells exposed to 2 across a 72 h time series. Data
previously published for osmium complex FY26 are also included for
comparison.6 RFI values o1 indicate a drug-induced decrease in protein
levels, RFI = 1 indicates no-drug eﬀect and RFI4 1 indicates drug-induced
increases in protein levels.
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
2/
12
/2
01
7 
14
:0
0:
32
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Metallomics This journal is©The Royal Society of Chemistry 2017
a 72 h time series. This was compared to data previously
reported for FY26 (complex 3).
Fig. 7 shows that complex 2 induced high levels of IAP
proteins, survivin and XIAP. Osmium complex 3 (FY26) also
induced these same proteins, however, to a much lower level.
BCL-X, which is a pro-survival protein located in the mito-
chondria, was down-regulated during most of the time series,
but up-regulated at 24 h, suggesting specific modulation of the
apoptotic pathway. Of the pro-apoptotic proteins, most were
down-regulated, however, BCL-2 and BAK, which are initiator
proteins, were up-regulated at 24 h. In addition, PARP cleaved by
CASP-3 (PARP*), was present in higher levels after 24 h, particularly
at the lower concentration of administered compound.
Flow cytometry studies were performed to determine the
level of apoptotic cells after exposure to 2. These experiments
measure the fluorescence of annexin V and propidium iodide
dyes, where the former identifies early apoptotic cells and the
latter identifies late-apoptotic and/or necrotic cells. During early
apoptosis, membrane-bound phosphatidylserine proteins, which
ordinarily face into the cytoplasm, translocate to the outside of
the cell membrane and allow annexin V binding.26 A cell in early
apoptosis, will still maintain its membrane integrity, there-
fore the DNA intercalator dye, propidium iodide, cannot pass
through. Once the cell has lost viability, its membrane becomes
permeable to propidium iodide, which fluoresces upon binding
to DNA.
Fig. 8 shows that there are diﬀerent levels of apoptosis after
24 and 48 h exposure to 2. After 24 h exposure, there was a
slight decrease in cell viability, with a more significant decrease
when exposed to a higher dose of 2 (94.2%) compared to the
lower dose (95.1%). There was a higher population of cells in
early apoptosis at the higher dose compared to the lower (2.0%
and 1.3%, respectively), but a lower number of late apoptotic
(1.1% and 1.5%) and necrotic cells (2.2% and 2.3%).
After 48 h there was a more significant drop in cell viability,
now down to 58.0% at 0.13 mM and 56.4% at 0.40 mM com-
plex 2. There were on average, a larger population of cells in
late apoptosis at the higher dose of 2 compared to the lower
dose, 41.2% and 30.2%, respectively. However, there were more
necrotic cells present after exposure to the lower dose of 2, 11.8%
and 2.5%.
Imaging
High content screening was used to further explore the mecha-
nism of cell death in A2780 and OVCAR-3 ovarian cancer cells
after 48 h exposure to various concentrations of 1 and 2.
Fig. 6 Comparison of the eﬀects of iridium complex 2 and osmium complex 3 on the population of the various phases of the A2780 cell cycle. Cell
populations for control samples are shown in blue and those for 24 h 2-exposed samples in green and 3-exposed in brown. * Indicates p o 0.10,
** indicates p o 0.05 and *** indicates p o 0.01 after a Welch two sample t-test between control- and compound-exposed samples in each stage of
the cell cycle.
Fig. 7 Apoptosis investigations. Heat map showing the relative fluores-
cence intensity (RFI) values for a selection of apoptotic proteins in A2780
cells exposed to 2 across a 72 h time series. Data reported for 3 (FY26) are
presented for comparison.
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After this period, adherent cells were stained with DAPI, a blue
stain for nuclear DNA, and Nucviewt488, a caspase 3 biosensor
that becomes activated and fluorescent upon endogenous caspase
activation inside the cell. Fig. 9 shows representative microscopy
images of caspase 3 positive apoptotic cells following exposure to
2.5 mM 1 and 2 for 48 h.
A2780 cells exposed to 1 and 2 show very diﬀerent levels of
apoptosis, with 1 inducing very little cell death compared to the
DMSO control. Complex 2 shows significantly higher activity in
both ovarian cell lines compared to 1, particularly at the higher
concentration of 2.5 mM (representative images in Fig. 9).
Comparing cell lines provided interesting results and high-
lights the diﬀerence in cell selectivity between 1 and 2. In A2780
cells, 1 was inactive and 2 was highly active in reducing cell
count, however, in OVCAR-3 cells the cell count reduction was
more comparable (results not shown). In general, the activity of
complexes at the single cell level27 depends on the metal itself,
its oxidation state, the types of metal and numbers of bound
ligand atoms, and the coordination geometry.28,29 Some com-
plexes can be relatively inert and might reach the target site
intact (as administered), but in general metal complexes are
pro-drugs and may undergo metal- or ligand-based redox reac-
tions as well as ligand substitution reactions before they reach
targets.30,31
Discussion
Since we have adopted a phenotypic screening approach, attempt-
ing to optimise the design of complexes based on their chemical
properties and their activity, the next stage after discovery of active
complexes is to elucidate the nature of their MoA to guide further
chemical optimization and/or patient selection strategies. In
the present case our approach assessed correlations between
anticancer activity and cell line gene mutations comparing
patterns of activity with a range of previously screened com-
pounds with known target sites. Comparing just the patterns
of activity has already been fruitful on the smaller scale of the
Fig. 8 The populations (%) of the various stages of apoptosis/cell death
after exposure of A2780 human ovarian cancer cells to 0.13 mM (purple) or
0.40 mM (green) organo-iridium complex 2 for 24 h (top) and 48 h (bottom).
Fig. 9 Fluorescence images showing caspase positive apoptotic A2780 (A) and OVCAR-3 (B) human ovarian cancer cells 48 h after exposure to no added
compound (control), 2.5 mM 1 and 2.5 mM 2. DAPI stains nuclei of cells (blue), and NucViewt reagent stains caspase activity in apoptotic cells (green).
Metallomics Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
3 
N
ov
em
be
r 2
01
7.
 D
ow
nl
oa
de
d 
on
 2
2/
12
/2
01
7 
14
:0
0:
32
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
Metallomics This journal is©The Royal Society of Chemistry 2017
NCI-60 cell line screens.8 In general, metallodrugs are likely to
be multi-targeted, attack several biochemical pathways simulta-
neously, and require a systems pharmacology approach for
analysis of activity.32 We also compare these iridium complexes
with two organo-osmium complexes for which we also have
Sanger screening data. This comparison highlights the remark-
able influence of the azopyridine ligand on activity.
In the present case, the major diﬀerence between complexes
1 and 2 is the change in the chelated ligand from a negatively-
charged C,N-bound phenylpyridine (1) to a neutral N,N-bound
N-dimethylphenylazopyridine (2). Hence the overall charge
on the complex changes from 0 (neutral) to +1. However, we
previously reported that replacing only one atom from the
N,N-chelating ligand 2,20-bipyridine in the Ir(III) pentamethyl-
cyclopentadienyl complexes to a C,N-chelating ligand phenyl-
pyridine leads to a significant increase in anticancer activity.28,33
Therefore, the change in charge on the complex seems not to play
a vital role in the control of their anticancer activity. In addition,
we found that potency toward cancer cells increased with
additional phenyl substitution on the Cp* ring: CpXbiph 4
CpXph 4 Cp* for the cyclopentadienyl Ir(III) complexes.10
Complex 1 also has an additional phenyl substituent on the
cyclopentadienyl ring, which not only enhances lipophilicity
but can also intercalate between DNA bases if that is an attack
site. However, interestingly, the CpXph complex 2 displayed a
more potent antiproliferative activity than the CpXbiph complex 1.
It seems that the azopyridine ligand plays a major role in the
anticancer activity.8 The azopyridine ligand is a strong p-acceptor,
withdrawing electron density from themetal. This makes complex
2 (as well as 3 and 4) more inert towards hydrolysis than complex
1, which more readily undergoes aquation (replacement of mono-
dentate chloride with water) in aqueous media and leads to
deactivation before reaching its biological targets.30
We have also shown previously for Os complexes 3 and 4,
that the additional phenyl group in 4 increases activity, but
does not play a key role in the MoA. It is likely to increase cell
uptake, resulting in a more potent compound.34 This has also
been shown for Ir complexes.9
Our previous work has shown the diﬀerence in activity between
neutral complex 1 and a charged analogue, [Ir(Z5-CpXbiph)(ppy)py]+,
in which the Cl ligand is substituted by pyridine. The charged
complex has a higher potency, however, this was linked to the
slower hydrolysis of the Ir-py bond, which aﬀected the down-
stream MoA. However, in contrast, the Ir–Cl bond in complex 2
does not readily undergo hydrolysis. Thus even though pre-
vious work has demonstrated the importance in the Ir–Cl
bond, the bidentate ligand seems to have a dominant effect,
in line with the high activity of the Os-azopyridine complexes 3
and 4.21
Pharmacogenomic screening
The antiproliferative potency of organo-iridium complexes 1
and 2 compared to CDDP towards the wide variety of cancer cell
lines in both the NCI-60 and Sanger – ca. 900 cell lines follows the
order: 24 CDDP4 1. Both the lipophilicity and overall charge
on a complex can have a major effect on its biological activity.
This trend is also apparent for patient-derived cancer cell lines
which display distinct sensitivities to platinum agents (Table 3),
where 1 has poor activity in all 3 cell lines, particularly in CDDP-
resistant cell lines with an IC50 value 4100 mM. These results
show that complex 2 and not 1 would therefore be a candidate
for combating platinum-resistant cancers and suggest that
complex 2 might have a non-DNA-based MoA, unlike CDDP.
The Sanger screen was used to identify cell lines of interest
and to correlate activity with similarities in cell line genetics to
explore the MoA. It is apparent that 2 has a novel pattern of
activity compared to other drugs in the Sanger screen for which
data are available (Table 2). It is the only drug to have a sensitivity
association with mutations in the KIT gene,34,35 primarily found
in NSCLC. KIT encodes C-KIT, an important cytokine receptor
commonly associated with blood and bone cancers.36 Once the
receptor is activated it controls signalling for cell survival, pro-
liferation and diﬀerentiation. KIT mutations have been asso-
ciated with an increased sensitivity to imatinib and has been
proposed as an important biomarker in imatinib treatment.37
Functional C-KIT often confers chemoresistance by augmenting
the expression of DNA repair genes. The mutated KIT gene may
therefore render cells more sensitive to DNA damage, consistent
with DNA attack being partly responsible for the activity of 2, as
discussed further below.38
Interestingly, the Sanger screen highlighted a significant
similarity between 2 ([Ir(Z5-CpXph)(azpy-NMe2)Cl]
+) and two pre-
viously studied Os complexes: FY12 ([Os(Z6-bip)(azpy-NMe2)I]
+)
(4) and FY26 ([Os(Z6-p-cym)(azpy-NMe2)I]
+), (3), Fig. 1, suggesting
that their activity is closely linked to the azpy-NMe2 ligand,
which is conserved across all three compounds. Moreover since
Ir(III) and Os(II) are isoelectronic (outer shell electronic configu-
ration 5d6) and the complexes have similar 3D structures, global
charges and probably log p values, it might be expected that
they have similar profiles of biological activity. Although the
activity of 2 does not correlate with that of any other drugs
screened, those of organo-osmium complexes FY12 and FY26
do. Particularly noteworthy is the similarity in activity between
FY26, bleomycin and SN-38 (the active metabolite of irinotecan,
Camptosar), where cell lines with R184 amplifications are more
resistant to all three compounds. Bleomycin, used in the treat-
ment of testicular, cervical, lymphoma and cancers of the head
and neck, causes both single- and double-DNA strand breaks in
cancer cells.39 It can chelate iron, bind to DNA and react with
oxygen to produce ROS, which damage DNA.
Topoisomerase enzymes are required for the unwinding of
supercoiled DNA and the cutting and re-ligation of DNA during
replication and protein synthesis. The active metabolite of
irinotecan, SN-38, is a topoisomerase I (TOP1) inhibitor.40 TOP1
relaxes supercoiled DNA during replication and transcription,
and generates and ligates cleaved single strands. Inhibitors of
TOP1 prevent the ligation of cleaved strands, maintaining DNA
breaks and activating cell death mechanisms in cancer cells.
Oxidative stress
The mitochondrion is the biggest source of ROS production in
the cell, and mutations in OXPHOS machinery in A2780 cells
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perpetuate ROS production.41 NRF2 is up-regulated in response
to 2, and we have shown by flow cytometry that this compound
induces a significant ROS response. SO is normally converted to
oxygen and H2O2 by superoxide dismutase (SOD), which is then
broken down by catalase (CAT) to water and oxygen.42 Neither
CAT nor SOD genes were up-regulated after exposure to 2. In
fact, CAT was expressed in higher levels in the control samples,
highlighting the oxidatively-stressed nature of A2780 cells, and
that no response to H2O2 was mobilised after compound
exposure. Disruption of CAT and SOD function has been shown
to have a knock-on eﬀect on the function of other antioxidant
enzymes, potentiating the damage caused by ROS.43 The down-
regulation of key response genes suggests that 2 induces ROS
production and also reduces the ability of A2780 cells to respond
to excessive ROS.
The production of ROS frommitochondria has a cyclic eﬀect
on the function of mitochondria, potentiating the production
of higher levels of ROS.44 These ROS can damage mtDNA and
proteins within the mitochondria, in addition to disrupting
the polarisation of the mitochondrial membrane.45 Mitocans,
which target the bioenergetics of cancer cells and increase ROS,
are becoming a focus of anticancer drug development.46 ROS
generation by 2may also occur by other mechanisms, as well as
through mitochondria, ROS production during cell stress is
well documented, and occurs indirectly in response to many
drugs, including CDDP.47
Complex 2 shared similarity in its stress response to the
organo-osmium complex FY26, 3. The Sanger screen points to
close similarities in their MoAs. Previous experiments on FY26
have likewise demonstrated induction of ROS in A2780 cells.6 It
seems clear that the azpy ligand plays a central role in inducing
ROS by both these organo-iridium and organo-osmium com-
plexes, however, the diﬀerences between the two structures causes
a diﬀerence in ROS responses at the gene and the cellular level,
with complex 2 resulting in high levels of total ROS but reduced
levels of SO compared to FY26, and subsequently diﬀerent
transcriptional responses being activated.
Recently we have shown that although organo-osmium
complex 3 is relatively inert in aqueous chemical solutions,
it is activated in cancer cells and the iodide ligand is rapidly
pumped out, and studies by nanofocussed X-ray fluorescence
spectroscopy show that osmium from complex 3 localises in the
mitochondria of human ovarian cancer cells.48,49
DNA damage and cell cycle arrest
Cells are equipped with mechanisms to repair DNA damage,
however, ovarian cancers often lack the proper tools for DNA
damage repair (DDR).50 Resistance to conventional platinum
therapy often originates from the ability of cancer cells to repair
DNA lesions caused by CDDP, even in cell lines with DDR
deficiencies.51 DNA damage caused by CDDP is often not selec-
tive for cancer cells, and can be just as damaging to normal cells,
especially with high-dose CDDP. In contrast, it is also possible to
damage DNA through indirect mechanisms, and DNA is a well-
known target for ROS, particularly guanine bases.52 DNA damage
caused indirectly by anticancer compounds, through selective
ROS generation, could provide a more targeted approach to
achieving this MoA.
There was measurable protein activation of DDR through
the ATM-CHK2-p53-p21 pathway, however, there was also acti-
vation of the BRCA1 protein. RPPA suggested either S or G2/M
phase arrest was possible in cells exposed to 2, with S and G2/M
phase protein markers up-regulated at 24 and at 72 h. Flow
cytometry experiments confirmed S phase arrest after 24 h
exposure (Fig. 6). BRCA1 is an important protein in the S phase
of the cell cycle during DNA damage and is required for
homologous recombination and DNA damage-induced S and
G2/M phase arrest.53 It could therefore follow that 2 does not
require functional p53 for its MoA, as it does not require cells to
be held in G1.
Collectively this could suggest that organo-iridium complex 2
has a more directed eﬀect on DNA by exerting its activity either
during DNA replication (S phase) or after the DNA content has
been doubled (G2 phase). Organo-osmium complex FY26 appears
to be most eﬀective prior to DNA replication (G1 phase), and
therefore may not have a DNA-focussed MoA.
Apoptosis
Modes of cell death can often be distinguished using whole cell
imaging techniques.54 However, specific protein and gene
markers can also be studied. For example, apoptosis is normally
characterised by caspase production, and by distinct budding of
cell membrane structures into so-called apoptotic bodies. In
contrast, oncosis involves swelling and not shrinking of the cell
and is caused by non-specific cell injury.55 Necrosis is commonly
identified as its own mode of cell death, but in fact necrosis is
the last stage in any cell death pathway, i.e. both oncosis and
apoptosis lead to necrosis and cell death.
Most anticancer agents aim to activate apoptosis in cancer
cells, simply because this is the most controlled form of cell death,
involving phagocytosis in the final stages. However, cancer cells
often develop mechanisms to evade apoptotic cell death which
serves to highlight the merits of alternative mechanisms, like
pyroptosis, an immune-induced mechanism of cell death.56
RNAseq data suggested poor transcriptional activation of apop-
totic caspase markers by 2, but some transcription of apoptotic
initiators. RPPA further supported this conclusion, with waves
of apoptotic initiation towards the middle of the time course,
followed by recovery towards the end (Fig. 7). By comparison,
FY26 showed even less up-regulation of apoptotic components.
Late apoptosis was detectable by flow cytometry for 2-exposed
cells at the 48 h time point. However, by 72 h, the cell population
had recovered viability. This supports an occurrence of a wave of
cell death. Using high content screening (HCS) to detect levels of
caspase-3, the eﬀector-phase of apoptosis was explored. HCS
proved to be a useful method in visualising cell death for multiple
compounds; it was possible to extract compound-based trends
and make predictions about the level of apoptosis at higher
concentrations, where there was a significant increase in apopto-
tic cells at higher concentrations for 2 compared to 1. ROS release
has been shown to modulate apoptosis and may therefore play a
central role in delaying apoptosis.57
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Conclusions
Screening of two organo-iridium complexes in the Sanger screen
of 916 cancer cell lines revealed a remarkably high potency for the
phenylazopyridine complex 2 compared to the phenylpyridine
organo-iridium complex 1 and the clinical platinum drug cisplatin
(CDDP).
The screen also revealed a particularly high susceptibility of
triple negative breast cell lines to 2, and potential correlations to
ROS-inducing drugs. Notably the pattern of activity of 2 towards
the wide range of cancer cell lines was diﬀerent to 253 previously
screened drugs suggesting an unusual MoA, but remarkably
similar to organo-osmium complex FY26 which shares the same
N,N-chelated phenylazopyridine ligand.
The MoA for both iridium complex 2 and osmium com-
plex 3 appears to involve the rapid generation of ROS in cells,
and can achieve selectivity for cancer versus normal cells since
cancer cells have defective mitochondria, the usual source of
ROS. However, more interesting is the diﬀerence in the exact
nature of the ROS response triggered; with complex 2 inducing
less of a superoxide response. This diﬀerence in the induction
of ROS caused cells to arrest in S/G2 phase in response to 2,
whereas for 3 cells arrested in G1. Apoptosis seemed to be
apparent after longer exposure periods, with interesting pro-
and anti-apoptotic protein dynamics measured across the time
series.
Ultimately this study provides a clear example of the benefits
of combining diﬀerent theoretical and experimental methods
to explore novel and complex MoAs. In particular the combi-
nation of such methods can allow the separation of intricate
diﬀerences in activity between compounds to interpret pheno-
typic response at molecular and cellular levels, which inform
further preclinical development and clinical translation.
Materials and methods
Compound synthesis and characterisation
All compounds were synthesised and characterised as described
previously.8,21,33
Antiproliferation assays
Complexes 1 and 2 were screened under the ‘Genomics of
Drug Sensitivity in Cancer’ project at the Sanger Institute
(Cambridge, UK).
Briefly, cells were seeded in 96 well plates at ca. 15%
confluency and left to incubate for 24 h at 310 K, 5% CO2,
95% air and 100% relative humidity. Cells were treated with
nine concentrations of each compound and returned to the
incubator for 72 h. For suspension cell lines, cells were treated
with compound immediately following plating, and returned to
the incubator. Cells were stained and quantitation of fluores-
cent signal intensity was performed using a plate reader.
IC50 values were returned to The University of Warwick for
downstream analysis. MANOVA analysis was performed by the
Sanger Bioinformatics Institute.
Primary cancer cell screening
Primary patient cell lines were seeded in 96 well plates with
ca. 5000 cells per well in RPMI-1640 with 1% (v/v) 2 mM
glutamine. The plates were incubated at 310 K for 48 h. Stock
solutions of each compound were prepared and cells exposed
across a dose range for a further 48 h. Cells were extracted and
the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay (Life Technologies) was used to determine cell
viability.
RNA sequencing
TruSeq kits (Illumina) were used to prepare samples for sequen-
cing as per the manufacturer’s guidelines. From total RNA, mRNA
samples were purified, fragmented and reverse transcribed to
cDNA. Sequencing libraries were produced, with incorporated
barcodes to allow multiplexing. Samples were sequenced on an
Illumina Hiseq2000 instrument across 5 lanes (6 samples per
lane). 50 base pair, paired-end reads were recorded producing
ca. 60 million reads in total, per sample.
A2780 cells were seeded at 3  106 cells per 100 mm petri
dish. Plates were incubated for 24 h at 310 K, 5% CO2, 95% air
and 100% relative humidity. Complex 2 (400 nM) and vehicle
control solutions were added and after 4, 12, 24 and 48 h cells
were collected and whole-cell RNA extracted (RNeasy plus mini
kit, Qiagen). Samples were run on a NanoDrop 1000 spectro-
photometer machine and the absorbance at 230, 260 and
280 nm recorded to calculate the 260/230 and 260/280 ratios.
Samples with A260/2304 2.0 and A260/2804 1.9 were passed.
The concentration of RNA in each solution was also estimated
using the NanoDrop and was verified using a 2100 Agilent
Bioanalyzer and an RNA 6000 Nano Kit (Agilent), and the Qubit
assay (Life Technologies). All samples had a RNA integrity
number (RIN)4 9.50. A minimum of 1 mg RNA for each sample
was transferred to Oxford Genomics Centre (Wellcome Trust
Centre for Human Genetics) in a total of 30 mL RNase free water
in skirted 96 well plates.
Data deposition: the sequencing data reported in this paper
have been deposited in ArrayExpress (accession E-MTAB-5991).
Data analysis
Preliminary filtering was performed on the data to remove all
samples with quality scores (Q) o 20. FASTQ files for the
forward and reverse reads were integrated and aligned to the
hg19 (GRCh37) human genome using TopHat2. Files were
returned to The University of Warwick in BAM format. Samtools
(version 0.1.19-44428cd) was used to explore the raw BAM files,
extracting chromosomal reads and summary statistics. BAM files
were sorted by read name and then converted to SAM format.
HTSeq (version 0.5.4p5) was used to map the read locations to
genomic regions using the hg19 genome construct with the
intersection-nonempty program option. Resulting mapped files,
were then analysed for diﬀerential gene expression using the
edgeR package (version 3.1.10) in the R statistical programme
(version 3.0.2). A list of diﬀerentially expressed genes was
obtained for each time point (4, 12, 24 and 48 h) and used
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together with Ingenuity Pathway Analysis software to assign
significantly expressed genes to biological pathways.
Reverse phase protein microarrays (RPPA)
4  105 A2780 cells were seeded per well and cells were pre-
incubated in drug-free media for 48 h. After this, cells were
treated at 150 nM and 450 nM for 4, 24, 48 and 72 h. Control
samples were treated with media containing 0.1% DMSO. Cell
lysates were collected and deposited onto a Zeptosens chip.
Chips were blocked and washed prior to performing a dual
antibody immunoassay comprising of a 24 h incubation of
primary antibodies followed by 2.5 h incubation with secondary
Alexa-Fluor 647 conjugated antibody detection reagent. The
immunostained arrays were imaged using the ZeptoREADER
instrument and analysed using ZeptoView 3.1 software. Local
normalisation of sample signal to a reference BSA grid was used
to compensate for any intra- or inter-array/chip variation. RFI
values were further normalised to a house keeping protein
(prohibitin) and to the negative control, to provide the final
RFI to represent the relative abundance of total, phosphorylated
and cleaved proteins in compound-treated samples relative to
the DMSO control for each time point.
Apoptosis assays
A2780 cells were seeded at 1  106 cells per well in 6-well plates.
Cells were preincubated in drug-free media at 310 K for 24 h in
a 5% CO2 humidified atmosphere. Drug/compound solutions
were added and the cells left to incubate for a further 24, 48 or
72 h. Following exposure, the drug-containing medium was
removed, and cells were washed, harvested and stained with
Annexin V FITC and propidium iodide (Biovision, Annexin
V-FITC Apoptosis Kit) according to the manufacturer’s instruc-
tions. Control samples stained with just propidium iodide or
Annexin V FITC were also included for compensation purposes.
The samples were analysed using Beckton Dickinson FACScan
with fluorescence detection running Cell Quest software (20 000
events were collected from each sample). Data were processed
using Flowjo software (version 7.2.5).
Cell cycle analysis
A2780 cells were seeded at a density of 1  106 cells per well in a
6-well plate and pre-incubated in drug-free media at 310 K for
24 h in a 5% CO2 humidified atmosphere. Drug solutions were
added and the cells left to incubate for a further 24 h. Cells were
collected and washed twice with PBS. Cells were fixed with 70%
ethanol and stored at 293 K for 24 h. For analysis, cells were
transferred into PBS, incubated with RNase (0.2 mg mL1) and
propidium iodide (0.05 mg mL1) for 40 min at 310 K and then
analysed by flow cytometry using a Beckton Dickinson FACScan
with fluorescence detection. The resulting DNA histograms
were quantified using the FlowJo software (version 7.2.5).
High content screening (HCS)
Compounds 1 and 2 were imaged by HCS at The Edinburgh
Cancer Research Centre. Cells were seeded in a 96-well plate at
5000 cells per well and incubated for 48 h before treatment with
each compound for a further 48 h. Prior to image acquisition,
cells were incubated with 4 mg mL1 DAPI (Sigma D8417), and
1 mMNucViewt (Biotium) reagent for 0.5 h. Microscopic images
of DAPI and NucViewt stained cells were acquired with a 10
objective and appropriate optical filters using the Olympus ScanR
high-content imaging microscope. Merged images of DAPI and
Nucviewt cells were created using the Olympus ScanR imaging
software Cell-IRt.
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